Nuclear positivity for PPAR gamma in tissue microarray section of ductal carcinoma in-situ (DCIS) of the breast

<p><b>Copyright information:</b></p><p>Taken from "COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ"</p><p>http://www.biomedcentral.com/1471-2407/8/36</p><p>BMC Cancer 2008;8():36-36.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2254431.</p><p></p> Original magnification, ×400

Strong COX-2 positivity on immunohistochemical staining in tissue microarray section of ductal carcinoma in-situ (DCIS) of the breast

<p><b>Copyright information:</b></p><p>Taken from "COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ"</p><p>http://www.biomedcentral.com/1471-2407/8/36</p><p>BMC Cancer 2008;8():36-36.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2254431.</p><p></p> Original magnification, ×400

KingClonalityCode

This file contains the R code used to preprocess the SNP array files (not submitted due to privacy issues) as well as the clonality analysis using the submitted log-ratio data

KingClonalityData

Number log-ratio data for the 31 samples in the manuscript. It is a gzipped text file

Additional file 1: Table S1. of Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

Association between first breast cancer HR status and CBC, among women not receiving tamoxifen for first diagnosis. In the WECARE Study population of women who had not received tamoxifen for their first breast cancer diagnosis, having an ER-negative first breast cancer or a PR-negative first breast cancer statistically significantly increased the risk of CBC. (DOCX 19 kb

Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman Spectroscopy

White adipose tissue inflammation (WATi) has been linked to the pathogenesis of obesity-related diseases, including type 2 diabetes, cardiovascular disease, and cancer. In addition to the obese, a substantial number of normal and overweight individuals harbor WATi, putting them at increased risk for disease. We report the first technique that has the potential to detect WATi noninvasively. Here, we used Raman spectroscopy to detect WATi with excellent accuracy in both murine and human tissues. This is a potentially significant advance over current histopathological techniques for the detection of WATi, which rely on tissue excision and, therefore, are not practical for assessing disease risk in the absence of other identifying factors. Importantly, we show that noninvasive Raman spectroscopy can diagnose WATi in mice. Taken together, these results demonstrate the potential of Raman spectroscopy to provide objective risk assessment for future cardiometabolic complications in both normal weight and overweight/obese individuals

Uncertainties and controversies in axillary management of patients with breast cancer

The aims of this Oncoplastic Breast Consortium and European Breast Cancer Research Association of Surgical Trialists initiative were to identify uncertainties and controversies in axillary management of early breast cancer and to recommend appropriate strategies to address them. By use of Delphi methods, 15 questions were prioritized by more than 250 breast surgeons, patient advocates and radiation oncologists from 60 countries. Subsequently, a global virtual consensus panel considered available data, ongoing studies and resource utilization. It agreed that research should no longer be prioritized for standardization of axillary imaging, de-escalation of axillary surgery in node-positive cancer and risk evaluation of modern surgery and radiotherapy. Instead, expert consensus recommendations for clinical practice should be based on current evidence and updated once results from ongoing studies become available. Research on de-escalation of radiotherapy and identification of the most relevant endpoints in axillary management should encompass a meta-analysis to identify knowledge gaps, followed by a Delphi process to prioritize and a consensus conference to refine recommendations for specific trial designs. Finally, treatment of residual nodal disease after surgery was recommended to be assessed in a prospective register.</p